Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

"NEOadjuvant Plus Adjuvant Therapy with Combination or Sequence of Vemurafenib, CobImetinib, and AtezolizuMab in Patients with High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma"

Next Previous
Trial Profile

"NEOadjuvant Plus Adjuvant Therapy with Combination or Sequence of Vemurafenib, CobImetinib, and AtezolizuMab in Patients with High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma"

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 12 Sep 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
  • 12 Sep 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top